Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (IT) cohorts in combination with Pembrolizumab. Overall the study aims to recruit up to 100 patients across around 10 trial sites in the United States and Australia.
Imugene thrilled as first patients dosed in VAXINIA MAST combination study
